if gsk is producing enough raw relenza powder for 240m doses/yr as has been confirmed this week and can fill all orders- we could see quarterly royalties of $102m aust for BTA starting jan-march qtr 2010 or 408m for next calender yr assuming no other increases in production are bought forward. any guesses at fair valuation based on that figure for the near term.?
if gsk is producing enough raw relenza powder for 240m doses/yr...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)